
    
      Da Volterra develops DAV132, a novel therapeutic option preserving the intestinal microbiota,
      to prevent potentially life-threatening conditions such as CDI or emergence of
      antibiotic-resistant bacteria. Prevention of CDI remains critical unmet need, especially for
      patients at high risk of developing such infection.
    
  